AlerisLife's EBIT is $-28M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2022
Trailing 12 months ending Sep 30, 2022
The latest EBIT for ALR is $-28M as of September 2022. That compares with $3.6M in the prior-year period — down 889.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside AlerisLife's historical trend and sector peers before judging valuation or financial health.
Over the past year, ALR's EBIT moved from $3.6M to $-28M — a 889.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AlerisLife's operating scale or balance-sheet position.
Against Healthcare companies, ALR currently prints $-28M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at AlerisLife's growth, margins, and balance sheet.
A EBIT figure of $-28M for ALR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.
After noting ALR's EBIT ($-28M), review year-over-year change from $3.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.